Skip to content

Treatment Ringworm (tinea corporis) with polyherbal unani formulation

Therapeutic Evaluation of Unani polyherbal formulation in the treatment of Quba (tinea corporis)-A randomized open-labelled standard control clinical trial. - NIL

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/02/080348
Enrollment
40
Registered
2025-02-12
Start date
Unknown
Completion date
Unknown
Last updated
2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L089- Local infection of the skin and subcutaneous tissue, unspecified

Interventions

Intervention1: Unani polyherbal formulation i.e bekh-e-anjeerdasti babchi tukhme panwar narkachoor : Form: Soak 6 grams of each drug in 100 mL of water overnight. Zulal (decanted water) for oral use

Sponsors

Luqman unani medical college and hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patient diagnosed with tinea corporis clinically, as well as by KOH mount test without nail and scalp involvement. 2. BSA less then or equal to 20 percent. 3. Patient who are willing and able to provide informed consent.

Exclusion criteria

Exclusion criteria: 1. Presence of complications such as secondary bacterial infection of the lesions. 2. Patients already on topical and/or systemic antifungal treatment (1 week of topical therapy and/or 4 weeks of systemic antifungal therapy before baseline visit) 3. Patients with diabetes mellitus. 4. Immunosuppressant patients like AIDS/HIV infection. 4. Pregnant and lactating women. 5. Noncompliance with the trial protocol.

Design outcomes

Primary

MeasureTime frame
1. Change in Investigator s global assessment(IGA)of clinical responses (see annexure-II for details) 2. Mycological cure: Clinically suspected cases of tinea corporis will be confirmed by skin scraping and KOH preparation, by visualizing presence or absence of long, narrow, septate and branching hyphae under microscope at baseline and at the conclusion of trial. Timepoint: 14th, 28th and 42nd day.

Secondary

MeasureTime frame
1. Change in TCS (Total clinical score) (see Annexure-III for details) 2. Changes in Dermatology Life Quality Index (see Annexure-IV for details) Timepoint: 14th, 28th and 42nd day.

Countries

India

Contacts

Public ContactDr Salma Chaush
drmqkhan@yahoo.com9849438319

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026